Abstract
Secukinumab, an anti-IL-17A monoclonal antibody, is commonly used for the treatment of psoriasis. The IL-17A cytokine has been linked to immune-mediated disorders, and in the FIXTURE study, secukinumab had proven superior to placebo and etanercept in treating psoriasis. Side effects of secukinumab could include neutropenia, susceptibility to candida (including chronic mucocutaneous candidiasis), superficial dermatophytosis, worsening of Crohn's disease, and increased likelihood of tuberculosis. In this report, we assess a patient who has suffered from psoriasis for 30 years, and incorrectly injected the drug daily, instead of weekly, for her first five doses. In just two weeks following the overdose, the patient's Physician's Global Assessment decreased from 4 to 2, and the patient was continued on the drug after one month. This case report represents the high safety index of secukinumab in 300 mg dosing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
